Brief: Lee's Pharmaceutical Says Unit's New Drug Application Of Natulan Accepted For Review
08/05/2020 15:44
May 8 (Reuters) - Lee's Pharmaceutical Holdings Ltd
0950.HK :
* UNIT'S NEW DRUG APPLICATION OF NATULAN ACCEPTED FOR REVIEW
BY
NMPA
* GROUP EXPECTED TO SUBMIT PRIORITY REVIEW APPLICATION OF
NDA BY
END OF MAY 2020
Source text for Eikon: ID:nHKS40WBZD
Further company coverage: 0950.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lee's Pharmaceutical Holdings
See all newsHong Kong's Lee's Pharmaceutical H1 profit jumps on higher-margin product sales
Brief: Lee's Pharmaceutical Expects H1 Net Profit Of HK$85 Million-HK$95 Million
Brief: Lee's Pharmaceutical Says Investigational New Drug Application For ADC Project ZK2401 Accepted By NMPA
Brief: Ashlins Pharmaceuticals And Lee's Pharm Announce Exclusive License And Supply Agreement Valued At Up To $31 Million
Brief: Lee's Pharmaceutical Says Entered Licensing Agreement With Ashlins Ocular Pharmaceuticals